Excipient Selection Patents: Leaders, Trends & White Space 2026
Excipient Selection and Stabilization Patents: Who Leads and Where the Field Is Still Open
45.2% sits with five companies. The top 5 assignees combined account for 317 of the 702 records in scope — a concentrated field at the top, with a long tail below. Filings climbed from 40 records in 2017 to a peak of 92 in 2023. The 2021-2024 window shows the clearest complete-year growth signal: 43 records in 2021 rising to 66 in 2024, a 53% increase. Counts for 2025 and 2026 are still filling in and should not be read as a slowdown.
- 1F HOFFMANN LA ROCHE & CO AG92
- 2COHERUS ONCOLOGY INC88
- 3GENENTECH INC69
- 4UCB BIOPHARMA SPRL36
- 5HONG KONG KING FRIEND IND CO LTD32
See the full excipient selection and stabilization analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on excipient selection and stabilization patents
Who holds the most patents on excipient selection and stabilization?
One assignee leads the ranked field with 92 records, well ahead of fifth place at 32 and tenth place at 25. The top 5 combined hold 317 of the 702 records in scope, or 45.2%, and the top 10 combined reach 450 records, or 64.1%. Below that tenth position, ownership spreads into a long tail of companies and institutions with far fewer filings each, so freedom-to-operate work should prioritise the leaders before the tail.
Is the filing trend for excipient stabilization patents still growing?
Complete-year data shows growth: filings rose from 43 records in 2021 to 66 in 2024, a 53% increase, with a peak of 92 records in 2023. The 2025 and 2026 counts appear lower only because publication lags filing by roughly 18 months, so those years are still filling in rather than showing a genuine slowdown. Anyone tracking momentum should anchor conclusions to 2024 or earlier.
What patent classes cover excipient selection and stabilization technology?
A61K, medicinal preparations, covers 87.9% of the 702 records in scope, and C07K, peptides and proteins, covers 53.3%, together confirming this is primarily a biologics-formulation field. A61P, therapeutic activity, appears on 18.5% and C12N, microorganisms and genetic engineering, on 10.1%. Smaller classes such as A61J (containers), C12Q (enzyme/DNA testing), G01N (material analysis) and C07D (heterocyclic compounds) each cover under 3% of records and mark narrower adjacent claim areas.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Excipient Selection and Stabilization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.